Two injections, two different jobs in your knee

If you have been told you need one of these injections — or are weighing one against the other — the most useful thing to understand first is that ChondroFiller and Arthrosamid do not compete for the same problem. Each goes to a different part of the knee and does a fundamentally different job.

ChondroFiller injection is a cell-free collagen scaffold delivered by ultrasound-guided injection directly onto the articular cartilage surface — the load-bearing tissue that covers the ends of the bones. Once placed, it polymerises into a stable gel within 3–5 minutes. Over the following 6–12 months, that scaffold recruits the patient's own progenitor cells to lay down new cartilage matrix. The goal is structural restoration of a focal area of damage.

Arthrosamid (iPAAG) takes a different route entirely. It is injected into the synovial cavity — the fluid-filled joint space — where it integrates with the synovial lining and remains as a permanent mechanical cushion. It does not regenerate cartilage; it absorbs and distributes load across a joint where the lining has become inflamed and the surface worn more diffusely.

The anatomical split — cartilage surface versus synovial lining — is the single most important fact when deciding which treatment is relevant. Both are outpatient, ultrasound-guided procedures performed under local anaesthetic; neither involves surgery or a theatre admission. But applying Arthrosamid to a focal cartilage lesion, or ChondroFiller to a diffuse osteoarthritic joint, gives no meaningful clinical benefit. The distinction is about matching the treatment to the underlying pathology, not about brand preference. Patient selection is where that distinction becomes practical.

Patients suited to ChondroFiller injection

Focal cartilage damage and diffuse osteoarthritis are not simply different points on the same spectrum — they call for fundamentally different treatments. ChondroFiller injection is designed specifically for the former: a discrete, focal Grade III or IV articular cartilage lesion, typically up to approximately 3 cm² in area, though the scaffold volume can be extended to cover defects of up to around 6 cm².

The typical candidate is a younger or more active patient — often someone whose cartilage damage has a clear traumatic origin rather than long-term generalised wear. Osteochondral defects (OCD), post-meniscal injury lesions, and isolated load-bearing chondral defects identified on MRI are the most common presentations. Because the treatment works through matrix-induced chondrogenesis — the scaffold draws the patient's own progenitor cells into the defect to regenerate new cartilage matrix — the clinical goal is structural restoration of the cartilage surface, not symptom management alone. It is this regenerative intent that separates ChondroFiller injection from pain-targeting options such as Arthrosamid.

Joint mechanics must be sound before treatment. Significant ligament instability or uncorrected malalignment places abnormal load on the repair site and compromises outcomes; these problems need to be addressed before, not after, the scaffold is placed.

Unlike surgical cartilage repair procedures, ChondroFiller injection does not require bone drilling, a tissue biopsy, or a second treatment stage. The acellular collagen scaffold is placed under ultrasound guidance as an outpatient procedure. Precise pre-treatment MRI assessment of lesion size, depth, and border integrity is essential — that characterisation is typically completed at the initial clinical assessment to confirm whether a defect falls within the treatment's suitable range.

Patients suited to Arthrosamid

Generalised knee osteoarthritis — where wear is spread across the joint surface rather than confined to one focal area — is the condition Arthrosamid is designed for. The typical candidate has symptomatic KL Grade III or IV knee OA: pain that persists through activity and rest, demonstrable joint-space narrowing on imaging, and a history of conventional treatments that have not delivered lasting relief. Hyaluronic acid injections, physiotherapy, and anti-inflammatory medications are the usual steps that precede consideration of Arthrosamid.

Approved in Europe in 2021 specifically for knee osteoarthritis, Arthrosamid has attracted endorsement from the British Orthopaedic Association and is available through the NHS in some settings — markers of clinical acceptance that are worth noting for patients uncertain about its standing.

The mechanism is permanent and palliative rather than regenerative. Composed of 2.5% cross-linked polyacrylamide and 97.5% water, the hydrogel integrates with the synovial lining after a single injection and remains there. Its effect is mechanical: it cushions a joint lining that has become inflamed and is no longer able to buffer load effectively. Because integration takes time, meaningful pain relief typically builds gradually, with maximum benefit emerging at three to six months. Published open-label studies by Bliddal et al. — a six-month prospective cohort (2021) and a twelve-month follow-up (J Orthop Surg Res, 2024) — indicate that up to 70–80% of patients achieve significant pain reduction, with relief sustained at around two to three years from a single injection in most cases.

A 2022 case series by Maulana, Cole, and Lee (Journal of Arthritis, 11(3):024–026) reported reductions in patellofemoral bone marrow lesions following a single Arthrosamid injection, suggesting possible secondary anti-inflammatory effects. This remains a preliminary finding from a small series and is not yet an established mechanism.

Arthrosamid does not restore articular cartilage. Patients with an isolated focal defect — the profile described in the preceding section — are not suited to it; there is no synovial integration target for the hydrogel to act on, and the structural problem at the cartilage surface remains unaddressed. The appropriate comparison is not ChondroFiller injection versus Arthrosamid, but rather which joint tissue is damaged and what that tissue needs.

What the clinical evidence shows for each

Comparing efficacy figures for ChondroFiller injection and Arthrosamid requires a preliminary caution: the trials enrolled entirely different patients pursuing entirely different endpoints, so the numbers cannot be read side by side without context.

ChondroFiller injection

The most rigorous structural evidence comes from a 2025 PMC-indexed prospective study by Demmer et al., in which ChondroFiller-treated joints showed significantly better cartilage quality at follow-up arthroscopy than controls — median Outerbridge score 1.5 versus 3.0 (P = 0.006) and ICRS grade 1 versus 3 (P = 0.002). In published knee cohorts, IKDC scores improve by approximately 30 points on average; Jerosch et al. reported a mean gain of 32.4 points sustained at three-year follow-up, well above the 16.7-point minimal clinically important difference. Structural MRI follow-up yields MOCART scores of 81–84, reflecting more than 80% defect fill and good integration with surrounding native cartilage. Across published series at three to five years, 70–85% of patients achieve meaningful symptom relief. ChondroFiller holds a European CE mark as a Class III medical device; it does not hold FDA approval in the United States.

Arthrosamid

Arthrosamid's clinical programme centres on open-label studies by Bliddal et al. — a six-month prospective cohort (J Orthop Res Ther, 2021) and a twelve-month extension (J Orthop Surg Res, 2024;19(1):274) — reporting 70–80% of patients with knee OA achieving significant pain reduction at twelve months, with registry cohorts extending to two to three years. The evidence base is larger in volume than ChondroFiller's knee-specific trials but does not include structural MRI cartilage endpoints such as MOCART, because Arthrosamid is not designed to restore cartilage architecture. Arthrosamid is CE-marked and formally approved in Europe for knee OA.

No head-to-head trial

The headline percentage figures for both products look similar; they measure entirely different things in entirely different patients. No randomised controlled trial comparing them directly exists — not an unusual position in the injectable-device landscape, where trials are designed to demonstrate benefit over a control within a specific indication rather than against an alternative product serving a different one. Both injections have a credible published evidence base within their respective indications; neither should yet be described as having the depth of long-term RCT data that established surgical interventions carry.

Cost, procedure, and risks compared

Both procedures share the same outpatient format: ultrasound-guided injection under local anaesthetic, no general anaesthesia, and no hospital admission. Neither is currently NHS-funded, and neither is covered by major UK private insurers including Bupa and AXA, so patients should plan for self-funded costs.

ChondroFiller injection

Pricing typically ranges from £3,000 to £8,000 depending on defect size and the volume of scaffold required for adequate fill. Because the collagen material is acellular, no tissue biopsy is taken beforehand and no bone drilling is performed — the scaffold is placed directly onto the prepared defect surface under ultrasound guidance. On the risk side, the 2025 Demmer et al. prospective study found that fibrous tissue formation occurred only in overfilled defects; flush application was consistently free of it, underlining the importance of accurate volume delivery. Standard injection-related risks such as transient local swelling and mild post-procedure pain apply.

Arthrosamid injection

A single injection is priced at approximately £3,000–£4,000. Because the hydrogel is permanent and integrates with the synovial lining, prophylactic antibiotics are administered on the day of the procedure as standard practice — a routine precaution rather than a marker of elevated risk. Known risks include infection, allergic reaction (to the hydrogel, anaesthetic, or antibiotics), Baker's cyst swelling, and temporary injection-site discomfort.

Where a patient's MRI confirms both focal surface cartilage damage and synovial involvement, both injections can be performed in a single session — each acting on its own target tissue. The clinical reasoning behind that option is covered in the decision section below.

Lincolnshire Knee's Sleaford Regeneration Hub is equipped for both ultrasound-guided procedures on an outpatient basis.

Choosing between them, and what to do next

The clearest selection principle is anatomical. If MRI confirms a discrete, focal Grade III/IV cartilage defect — typically up to around 3 cm² — in a knee with stable mechanics and healthy surrounding borders, ChondroFiller injection is the candidate pathway; the aim is structural restoration over six to twelve months. If the presentation is diffuse symptomatic osteoarthritis where conventional injectables have delivered insufficient or short-lived relief, Arthrosamid becomes the appropriate discussion — the aim shifts to durable pain reduction at the synovial level rather than rebuilding cartilage architecture.

When MRI reveals both a discrete surface defect and significant synovial involvement, combining both injections in a single session is clinically feasible, since each acts on a different target tissue. That combination calls for a consultant's review rather than self-selection; the imaging needs to clearly support both roles before the decision is made.

Neither product is appropriate for end-stage diffuse OA, where the question is replacement rather than preservation. Both sit firmly in the joint-preservation layer of the treatment hierarchy — ahead of that conversation, not instead of it.

Reaching the right answer depends on a full picture: MRI review with cartilage mapping where indicated, a clear account of what has already been tried, and an honest assessment of what the joint can still support. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral — booking an assessment at lincolnshireknee.co.uk is a practical way to bring those threads together.